News
MBOT
0.8910
+1.26%
0.0111
Microbot Medical Outlines Regulatory Goals and Investor Cautions
TipRanks · 15h ago
Microbot Medical Anticipates Receiving 510(K) Clearance From FDA In H1 2025, And CE MARK Approval In H2 2025
Benzinga · 16h ago
MICROBOT MEDICAL - SEES RECEIVING 510(K) CLEARANCE FROM US FOOD & DRUG ADMINISTRATION IN THE FIRST HALF OF 2025, AND CE MARK APPROVAL IN H2 OF 2025
Reuters · 16h ago
Weekly Report: what happened at MBOT last week (0415-0419)?
Weekly Report · 3d ago
HC Wainwright & Co. Maintains Buy on Microbot Medical, Lowers Price Target to $7
Benzinga · 04/17 09:52
Analysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)
TipRanks · 04/16 11:41
Microbot Medical Price Target Cut to $7.00/Share From $8.00 by HC Wainwright & Co.
Dow Jones · 04/16 11:35
Microbot Medical Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/16 11:35
MICROBOT MEDICAL, INC. <MBOT.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $7 FROM $8
Reuters · 04/16 11:21
U.S. RESEARCH ROUNDUP-Advanced Micro Devices, Kroger, Tyson Foods
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Advanced Micro Devices, Kroger and Tyson Foods among companies with new targets. Analysts raise ratings and target prices on several companies. Boeing, Caterpillar and AIG among those with targets raised.
Reuters · 04/16 07:18
Microbot Medical operations remain on track amid Middle East tensions, shares up
Microbot Medical operations remain on track amid Middle East tensions, shares up 9.90% premarket to $1.11. The company's activities in Israel and other parts of the globe continue without interruption. Company believes that current planned timelines and milestones will be met.
Seeking Alpha · 04/15 12:52
MICROBOT MEDICAL: ACTIVITIES BOTH IN ISRAEL, USA AND OTHER PARTS OF THE GLOBE CONTINUE WITHOUT INTERRUPTION
Reuters · 04/15 12:32
MICROBOT MEDICAL: REGULATORY, CLINICAL, OPERATIONAL AND PRE-COMMERCIAL ACTIVITIES CONTINUE TO STAY ON TRACK DESPITE THE ON-GOING SITUATION IN ISRAEL
Reuters · 04/15 12:32
Microbot Medical Shares Status Following Recent Geopolitical Events; Says All Regulatory, Clinical, Operational And Pre-Commercial Activities Continue To Stay On Track Despite The On-Going Situation In Israel
All Regulatory, Clinical, Operational and Pre-Commercial Activities in Israel continue to stay on track. Company Believes that both Regulatory and Commercial Milestones to be Achieved in Accordance with the Company's Current Timeline. Microbot Medical is the developer of the LIBERTY® Endovascular Robotic Surgical System.
Benzinga · 04/15 12:31
Weekly Report: what happened at MBOT last week (0408-0412)?
Weekly Report · 04/15 10:57
Weekly Report: what happened at MBOT last week (0401-0405)?
Weekly Report · 04/08 11:02
Weekly Report: what happened at MBOT last week (0325-0329)?
Weekly Report · 04/01 11:00
Microbot Medical Q4 EPS $(0.26) Misses $(0.25) Estimate
Benzinga · 03/28 03:47
MBOT Stock Earnings: Microbot Medical Misses EPS for Q4 2023
Microbot Medical reported earnings per share of -26 cents. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -25 cents. Microbot Medical is not expected to report any earnings for the fourth quarter.
Investorplace · 03/28 02:53
Microbot Medical Inc <MBOT.OQ> expected to post a loss of 25 cents a share - Earnings Preview
Microbot Medical Inc expected to post a loss of 25 cents a share. The one available analyst rating on the shares is "buy" for the company. Wall Street's median 12-month price target for Microbot Medical is $8.00. The company is expected to report results on March 29.
Reuters · 03/27 20:19
More
Webull provides a variety of real-time MBOT stock news. You can receive the latest news about Microbot Med Inc through multiple platforms. This information may help you make smarter investment decisions.
About MBOT
Microbot Medical Inc. is a pre-clinical medical device company. The Company is specializing in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is primarily focused on leveraging its robotic technologies with surgical robotics to improve surgical outcomes for patients. Its technological platforms include LIBERTY and NovaCross. Using its LIBERTY Endovascular Robotic Surgical System, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. LIBERTY Endovascular Robotic Surgical System addresses the needs of interventional cardiology, interventional radiology and interventional neuroradiology markets.